Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
4,652.95
+133.95 (2.96%)
Jul 10 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,490.00 - 4,665.00
52 week 2,165.00 - 4,925.00
Open 4,530.00
Vol / Avg. 4.74M/2.64M
Mkt cap 27.42B*
P/E 29.45
Div/yield 10.21*
EPS 1.58*
Shares 589.32M
Beta     -
Inst. own     -
*GBP
Jul 30, 2014
Q2 2014 Shire Plc Earnings Release Add to calendar
Jun 23, 2014
Shire PLC AbbVie Proposal Conference Call
Jun 2, 2014
Shire Plc at Jefferies Global Healthcare Conference
May 14, 2014
Shire Plc at Credit Suisse Stockholm Consumer and Healthcare IR Day
May 7, 2014
Shire Plc at Deutsche Bank Healthcare Conference - Webcast
May 1, 2014
Q1 2014 Shire Plc Earnings Conference Call
May 1, 2014
Q1 2014 Shire Plc Earnings Release
Apr 29, 2014
Shire Plc Annual Shareholder Meeting
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 18.84% 28.69%
Operating margin 22.79% 35.13%
EBITD margin - 40.09%
Return on average assets 10.55% 18.10%
Return on average equity 18.44% 30.94%
Employees 5,338 -
CDP Score - 83 C

Address

Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN, ENG
Ireland
+353-1-4297700 (Phone)

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc. Effective May 12, 2014, the Company acquired Lumena Pharmaceuticals Inc.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Director
Age: 55
James Bowling Interim Chief Financial Officer
Age: 45
Jeffrey M. Jonas M.D. President - Regenerative Medicine
Age: 59
Tatjana May General Counsel, Company Secretary
Age: 47
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 65
Dominic Blakemore Non-Executive Director
Age: 44
William Burns Non-Executive Independent Director
Age: 65
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 60